Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Smustine + temozolomide versus temozolomide in newly diagnosed glioblastoma during concurrent chemoradiotherapy/adjuvant chemotherapy
ChiCTR2100041612Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of semustine and temozolomide in glioblastoma (GBM) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Safety and Progression-free survival. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
semustinetemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2100041612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041612.